

**15 NOV 2021****Chairman of the Egyptian Drug Authority:**

After perusal of:

- The law establishing the Egyptian Drug Authority promulgated by Law No. (151) of 20196, and its executive regulations.
- Law No. (127) of 1955 regarding the practice of the medical professions.
- Civil Service Law promulgated by Law No. (81) of 2016 and its executive regulations.
- Presidential Decree No. (18) of 2020 forming the Board of Directors of the Egyptian Drug Authority.
- The minutes of the Authority's Board of Directors meeting held in its session on 20/7/2020.
- The decision of the head of the Egyptian Drug Authority No. (255) of 2020, on forming a committee to manage the drug planning and policies fund at the Egyptian Drug Authority.
- And what was presented by the head of the Central Department of Operations.
- For the sake of work.
- 

**Decided****(Article 1)**

The travel of inspection committees from the Egyptian Medicines Authority shall be authorized to travel abroad to inspect factories for pharmaceuticals and supplies. At the request of the company that owns the agency or the legal representative of the foreign factory in Egypt, For the purpose of registering the pharmaceuticals and supplies with the Egyptian Drug Authority, or at the request of the Central Operations Department of the Authority to conduct a periodic inspection of the factory.

**(Article 2)**

The travel committee shall be formed from the inspectors of the Egyptian Drug Authority (from the relevant Departments), the formation of the committee shall be approved by the decree of Prof. Dr. / Chairman of the Egyptian Drug Authority.

**(Article 3)**

A fee shall be paid for the inspection services as indicated in the accompanying statement to this decision. It is deposited into the account of the Egyptian Drug Authority's accounting unit, and the company requesting the inspection shall bear all travel and transportation expenses of the committee members and their residence abroad throughout the inspection period.

**(Article 4)**

Committee members shall be prohibited from personally obtaining any benefit or consideration from the company requesting inspection under any name. In the event of a violation, the inspector shall be referred to investigation. The decision on the inspection report on the factory shall be suspended until the investigation is completed. If the investigation results in a conviction, the necessary legal measures shall be taken against the inspection member as well as the requesting company

**(Article 5)**

The Head of the Central Administration of Operations, the Head of the Central Administration of the General Secretariat of the Egyptian Drug Authority, jointly shall develop a proposal for the mechanism of instructions and executive procedures regulating receiving inspection requests.

The procedures followed for the travel of the inspection committees, and this mechanism shall be approved by a decision from the head of the Egyptian Drug Authority.

**(Article 6)**

This decision shall be effective from the date of its issuance, and all competent departments shall implement it, each within its jurisdiction, and all that contravenes its provisions shall be repealed.

**Chairman of the Egyptian Drug Authority**  
**Prof. Dr. Tamer Mohamed Essam**  
*(signature)*

Issued on: 15.03.2021



**CR: 353570**  
**Tax ID: 200-328-697**  
**ISO 9001-2015 Certified**



**15 NOV 2021**



The consideration of the financial proposal in US pharmaceutical factories outside the Arab Republic

US Dollars

| S | Geographical area            |           |
|---|------------------------------|-----------|
| 1 | Arab countries               | 20,000 \$ |
| 2 | Africa                       | 25,000 \$ |
| 3 | Europe including Turkey      | 40,000 \$ |
| 4 | Asia (except Arab countries) | 35,000 \$ |
| 5 | South and North America      | 65,000 \$ |
| 6 | Australia and New Zealand    | 55,000 \$ |
| 7 | Japan and Russia             | 45,000 \$ |



15 NOV 2021

**Egy Mark**  
CR: 353570  
Tax ID: 200-328-697  
ISO 9001-2015 Certified